Zdrowie i gospodarka · 10/03/1994
Prospective Grant of Exclusive License: Recombinant Pseudomonas Exotoxin Immunoconjugate Specifically Directed Against the Lewis Y Antigen
The National Institutes of Health (NIH) is contemplating the grant of a limited field of use exclusive license to Boehringer Mannheim Pharmaceutical Corporation for the invention embodied in U.S. Patent Application Number 07/596,289.